Asset Details
Do you wish to reserve the book?
Effectiveness and safety of a novel intranasal influenza vaccine in Chinese children: A phase IV multi-Center, randomized, double-blind, placebo-controlled clinical trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effectiveness and safety of a novel intranasal influenza vaccine in Chinese children: A phase IV multi-Center, randomized, double-blind, placebo-controlled clinical trial
Do you wish to request the book?
Effectiveness and safety of a novel intranasal influenza vaccine in Chinese children: A phase IV multi-Center, randomized, double-blind, placebo-controlled clinical trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effectiveness and safety of a novel intranasal influenza vaccine in Chinese children: A phase IV multi-Center, randomized, double-blind, placebo-controlled clinical trial
2025
Overview
A novel intranasal influenza vaccine named Ganwu® was approved in 2020 for children aged 3–17 years in China. This study aimed to conduct a phase IV clinical trial to assess the effectiveness and safety of this vaccine.
We conducted a multicenter, randomized, double-blind, placebo-controlled phase IV clinical trial to evaluate the effectiveness and safety of Ganwu® vaccine in children aged 3–17 years in China during 2023 to 2024 influenza season. The influenza-like illnesses (ILIs) were monitored in the vaccine and placebo groups during a follow-up period of seven months, and nasopharyngeal specimens from ILI cases were collected for laboratory confirmation of influenza virus. Primary endpoints included vaccine effectiveness against laboratory-confirmed influenza and ILI, with comprehensive safety monitoring throughout the study period.
The trial enrolled 6000 participants, randomly allocated in a 1:1 ratio to receive either Ganwu® or placebo. The vaccine's effectiveness in preventing laboratory-confirmed influenza was 46.8 % (95 % confidence interval [CI] 25.8 %–61.9 %), with specific effectiveness rates of 30.4 % against A/H1N1, 55.1 % against A/H3N2, and 84.6 % against B/Victoria. Laboratory-confirmed influenza was significantly less frequent in the vaccine group (hazard ratio 0.53, 95 % CI 0.38–0.74). Effectiveness of Ganwu® vaccine against ILI was 15.2 % (95 % CI -2.3 %–29.7 %). Safety assessments demonstrated comparable incidence of solicited adverse events (AE) between groups, with the incidence of grade three or higher AEs below 1 %. Among 12 reported serious AEs, none were attributed to vaccination.
Ganwu® vaccine provided moderate protection against laboratory-confirmed influenza among children with good safety profile.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Child
/ Children
/ China
/ Diaries
/ Female
/ Fever
/ Humans
/ Influenza A Virus, H1N1 Subtype - immunology
/ Influenza Vaccines - administration & dosage
/ Influenza Vaccines - adverse effects
/ Influenza Vaccines - immunology
/ Influenza, Human - epidemiology
/ Influenza, Human - prevention & control
/ Intranasal influenza vaccine
/ Male
/ Placebos
/ Safety
/ Vaccines
/ Viruses
